RENAL SOLUTIONS RECEIVES NEW PATENT FOR ZIRCONIUM COMPOUNDS IN NEW SORBENT CARTRIDGES

 

Warrendale, PA, November 12, 2003 – Renal Solutions, Inc., the leading provider of sorbent-based hemodialysis products and services, announces having received Patent No. US 6,627,164 B1, Sodium Zirconium Carbonate and Zirconium Basic Carbonate and Methods of Making the Same.  These patented compounds and methods of production are being utilized in the manufacturing of the new SORB and HISORB sorbent regenerative hemodialysis cartridges recently cleared by FDA.  These sorbent cartridges are enhanced versions of the current SORB and HISORB Cartridges and allow for higher dialysate flow rates and improved electrolyte dynamics.  The Sorbent Cartridge is a key component of sorbent hemodialysis systems. The cartridges regenerate dialysate so that only 6 liters of potable tap water are necessary for an entire hemodialysis treatment.

 

“We are very pleased to have received this patent,” said Peter M. DeComo, Chairman and CEO of Renal Solutions.  “This patent reaffirms the significance of our progress and continued development of sorbent regenerative dialysis technology and validates our corporate implementation plan.” 

 

About the Company

www.renalsolutionsinc.com

 

Renal Solutions, Inc., a medical device and health-care service company, is developing a revolutionary technology/service solution for dialysis market and has a distinct competitive advantage as the only provider of dialysis products and services utilizing sorbent-based toxin removal technology.  Using sorbent dialysate regeneration; hemodialysis can be delivered in a variety of clinical settings. The sorbent hemodialysis system requires only 6 liters of potable tap water. This capability eliminates the need for complex technology to create a purified water source as with conventional dialysis technology.  The sorbent hemodialysis system is transportable and can be used anywhere 110V power and potable tap water can be accessed.  Renal Solutions is a privately held company focused on providing revolutionary products and service for renal failure patients that improve quality of life and aide in the reduction of the total cost of treatment. 

 

This press release contains forward-looking statements, which if not based on historical facts, involve risks and uncertainties.  Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control.  Events which could cause results to differ include, failure to meet on-going developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with the FDA/regulatory approval process, adverse changes to reimbursement, for the companies products/services and delays with respect to market acceptance of new products/services and technologies.  Other risks may be detailed from time to time but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.